Evidence Explorer · MS-N237 · Standardized botanical product · Supportive care · Appraised November 4, 2026
A large double-blind trial found no statistically significant primary result at four weeks but did find greater fatigue improvement at eight weeks with 2,000 mg/day of American ginseng.
Evidence at a glance
Benefit signal: Delayed eight-week fatigue improvement; four-week primary comparison missed significance
Certainty: Moderate for this product and schedule, but guideline confidence is limited by heterogeneous ginseng trials
Risk context: Insomnia, glucose and blood-pressure effects, bleeding interactions and product variability
What was studied
Three hundred sixty-four fatigued adults with cancer were randomized across 40 institutions to American ginseng 2,000 mg/day or placebo for eight weeks. The primary endpoint was the MFSI-SF general fatigue subscale at four weeks.
Change at four weeks was 14.4 versus 8.2 points (P=.07). At eight weeks it was 20.0 versus 10.3 (P=.003). Benefit appeared larger during active treatment, while reported toxicities did not differ significantly.
What this evidence cannot establish
The prespecified four-week primary comparison was not statistically significant, and subgroup findings during active treatment are less secure than the overall randomized comparison.
ASCO–SIO notes heterogeneity across ginseng species, preparations, doses and fatigue measures. American ginseng findings should not be generalized to Korean or Asian ginseng products.
Practical safety context
Review insomnia, diabetes, blood pressure, anticoagulation and possible CYP-mediated interactions. Product identity matters: root species, growing conditions, contaminants and ginsenoside profile vary.
Fatigue should not be assumed to be benign; infection, anemia, adrenal or thyroid dysfunction, sleep disorder and progression may require urgent evaluation.
Questions for the care team
- Is the proposed product Panax quinquefolius and chemically comparable to the trial product?
- Could it interact with anticoagulants, diabetes medicines or treatment?
- Has a reversible cause of fatigue been evaluated?
- What improvement by week eight would justify continuing it?
Funding and conflicts
The phase III trial was conducted through the North Central Cancer Treatment Group and supported by research funding described in the publication. No clear toxicity difference was observed, but product-independence and commercial sourcing still matter.
Sources
- Phase III randomized trial (PMID 23853057)
- ASCO–SIO cancer-fatigue guideline update (DOI 10.1200/JCO.24.00541)
- Related Missing Script review: American ginseng and cancer fatigue
Sources and publication status checked November 4, 2026. Last literature search: November 4, 2026; record appraisal: November 4, 2026.
For education, not personal medical advice. Research regimens are not personal prescriptions. Symptom, laboratory or biomarker changes do not establish tumor response, recurrence prevention or longer survival.
